ZIMHI®
(naloxone) Injection

Indication

ZIMHI® (naloxone) is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. ZIMHI is intended for immediate administration as emergency therapy in settings where opioids may be present. ZIMHI is not a substitute for emergency medical care.

ZIMHI technology video

ZIMHI Technology – watch our video that explains how it works

ZIMHI Resources

Instructions for Use

Full Prescribing Information

Visit ZIMHI.com

Scientific Articles

How to use ZIMHI

ZIMHI In The News

Yahoo! News | September 8, 2023: ‘Angel of West Palm Beach’ saves 19 people from overdose

Published ZIMHI Scientific Articles

Sign Up For DMK Pharmaceuticals Email Alerts

Choose Your Preferences

DMK Pharmaceuticals is a clinical stage neuro-biotechnology company focused on the development and commercialization of potential blockbuster products for the treatment of a variety of neuro-based disorders with significant unmet medical needs.

Linkedin Twitter

COMPANY

PRODUCTS

PIPELINE

INVESTORS & MEDIA

CONNECT

Adamis Pharmaceuticals logo

ADAMIS Announces Merger With DMK Pharmaceuticals

What is DMK?
Private, clinical-stage, neuro-biotech company
  • Focused on developing potential blockbuster products for underserved patients.
  • Product candidates selected and developed from proprietary library of approximately 750 small molecule neuropeptide analogues with broad utility.

Developing multiple first-in-class products targeting large unmet needs
  • Addiction
  • Acute and chronic pain
  • Parkinson’s disease
  • Bladder control
  • Other neuro-based diseases

Want to learn more?

Read our press release go to our Investor Relations page or visit https://dmkpharma.com/

Check this page for the most recent updates regarding the merger process.